Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.7640
-0.0139 (-1.79%)
At close: Jan 28, 2026, 4:00 PM EST
0.7640
0.00 (0.00%)
After-hours: Jan 28, 2026, 4:55 PM EST
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$74,571
Profits / Employee
-$1,541,878
Market Cap
18.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Aug 31, 2025 | 7 | 0 | - |
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| Lunai Bioworks | 29 |
| IN8bio | 17 |
| VYNE Therapeutics | 13 |
| ProMIS Neurosciences | 8 |
| Neuphoria Therapeutics | 8 |
| Allarity Therapeutics | 7 |
| Traws Pharma | 7 |
LEXX News
- 6 days ago - Lexaria Awarded Six Additional Patents - Accesswire
- 16 days ago - Lexaria Releases Annual Letter from the CEO - Accesswire
- 4 weeks ago - Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - Accesswire
- 5 weeks ago - Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
- 5 weeks ago - Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Accesswire
- 6 weeks ago - Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 6 weeks ago - Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Accesswire